PERINATAL TRIALS REPORT

PT0354

ACTOMgSO4 Trial

Australasian Collaborative Trial of Magnesium Sulphate for the Prevention of Mortality and Cerebral Palsy in Infants Born Very Preterm.

Plain Language Summary:      Infants born preterm have an increased risk of mortality and cerebral palsy. Evidence from recent case controlled studies support animal research that suggests maternal administration of magnesium sulphate may reduce the risk of cerebral palsy and mortality in infants born very preterm. It is important that these findings are tested in large randomised controlled trials as soon as possible to assess whether prophylactic treatment should be recommended for clinical practice in the case of women who are at risk of preterm delivery.

Trial status:                         Follow up complete

Date of accrual completion:    September 2001

Trial Objective:

To determine whether prophylactic treatment of magnesium sulphate may reduce the risk of mortality and cerebral palsy in infants born preterm.

Type of administration:        Multi-centre International

Prinicipal Investigator/s:      A/Professor Caroline Crowther

                                         Ph 61 8 8204 7647

                                         Email caroline.crowther@adelaide.edu.au

                                        A/Professor Janet Hiller

                                        Ph 61 8 8303 3573

                                        Email Janet.Hiller@adelaide.edu.au

                                        A/Prof Lex Doyle

Contact Person/s:               A/Professor Caroline Crowther

                                         Ph 61 8 8204 7647

                                         Email caroline.crowther@adelaide.edu.au

© IMPACT/PSANZ 2001